CR10736A - Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon - Google Patents

Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon

Info

Publication number
CR10736A
CR10736A CR10736A CR10736A CR10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A
Authority
CR
Costa Rica
Prior art keywords
antibodies
compositions
methods related
methods
treatment
Prior art date
Application number
CR10736A
Other languages
English (en)
Inventor
Hai Yan
Shaw-Fen Sylvia Hu
Thomas C Boone
Richard A Lindberg
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR10736A publication Critical patent/CR10736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgacion suministra composiciones y metodos relacionados con proteinas de union a antigenos, en particular, anticuerpos que se unen especificamente al receptor de glucagon de origen humano. La divulgacion provee acido nucleicos que codifican para dichas proteinas de union a antigenos y anticuerpos y metodos para preparar y utilizar dicho anticuerpo para el tratamiento y la prevencion de la diabetes de tipo 2 y trastornos relacionados mediante la administracion de dichos anticuerpos a un individuo que requiere dicho tratamiento.
CR10736A 2006-09-20 2009-04-17 Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon CR10736A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84620206P 2006-09-20 2006-09-20
US96897707P 2007-08-30 2007-08-30

Publications (1)

Publication Number Publication Date
CR10736A true CR10736A (es) 2009-06-30

Family

ID=39201088

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10736A CR10736A (es) 2006-09-20 2009-04-17 Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon

Country Status (19)

Country Link
US (2) US7947809B2 (es)
EP (1) EP2074149B1 (es)
JP (1) JP5513888B2 (es)
KR (1) KR20090059161A (es)
CN (1) CN101589062B (es)
AR (1) AR062895A1 (es)
AU (1) AU2007297652B2 (es)
BR (1) BRPI0715017A8 (es)
CA (1) CA2662613C (es)
CL (1) CL2007002668A1 (es)
CR (1) CR10736A (es)
EA (1) EA200970262A1 (es)
ES (1) ES2444012T3 (es)
IL (1) IL197241A0 (es)
MX (2) MX2009003093A (es)
NO (1) NO20091534L (es)
PE (1) PE20080846A1 (es)
TW (1) TW200820985A (es)
WO (1) WO2008036341A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091674A1 (es) * 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
CA2772590C (en) * 2009-09-08 2017-01-03 Neopharm Co., Ltd. Antibodies against glucagon receptor and their use
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
KR20160005749A (ko) 2013-05-07 2016-01-15 리나트 뉴로사이언스 코프. 항-글루카곤 수용체 항체 및 이의 사용 방법
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
AU2015243246B2 (en) * 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
AU2015273199B2 (en) * 2014-06-08 2020-09-10 REMD Biotherapeutics, Inc Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US9982061B2 (en) * 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
CN105669863B (zh) * 2014-12-05 2019-09-13 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
US10610504B2 (en) * 2014-12-23 2020-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
MX2017012694A (es) * 2015-04-02 2018-03-07 Remb Biotherapeutics Inc Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.
EP3344279B1 (en) 2015-09-04 2020-07-15 REMD Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20190062441A1 (en) * 2015-10-07 2019-02-28 Remd Biotherapeutics, Inc. Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
US20190002577A1 (en) * 2016-01-04 2019-01-03 Remd Biotherapeutics, Inc. Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
WO2018027084A2 (en) * 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MA46089A (fr) 2016-08-30 2019-07-10 Regeneron Pharma Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
MX2019008722A (es) * 2017-01-27 2019-10-02 Ngm Biopharmaceuticals Inc Proteínas de unión al receptor de glucagón y métodos para usarlas.
RU2019129174A (ru) * 2017-02-20 2021-03-22 Драгонфлай Терапьютикс, Инк. Белки, связывающие cd33, nkg2d и cd16
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN107011414B (zh) * 2017-05-31 2020-04-24 浙江省农业科学院 具有降血糖功能的三肽spf及其用途
MX2020002057A (es) 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2020023847A1 (en) 2018-07-27 2020-01-30 Ngm Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
MX2021007444A (es) 2018-12-21 2021-08-05 Jiangsu Hengrui Medicine Co Proteina biespecifica.
US20220235140A1 (en) * 2019-05-29 2022-07-28 Hedgehog, Inc. Antibody with enhanced binding affinity for endothelin receptor type a
MX2022001882A (es) * 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
WO2022182664A1 (en) * 2021-02-23 2022-09-01 10X Genomics, Inc. A method for epitope binning of novel monoclonal antibodies
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) * 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) * 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6909031B2 (en) 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
AU2006208286A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta

Also Published As

Publication number Publication date
US8158759B2 (en) 2012-04-17
IL197241A0 (en) 2011-08-01
JP5513888B2 (ja) 2014-06-04
CA2662613C (en) 2014-01-28
AU2007297652B2 (en) 2012-02-16
NO20091534L (no) 2009-04-28
EP2074149B1 (en) 2013-11-06
BRPI0715017A8 (pt) 2018-04-03
BRPI0715017A2 (pt) 2013-05-28
MX2009003093A (es) 2009-06-05
WO2008036341A3 (en) 2009-02-05
TW200820985A (en) 2008-05-16
WO2008036341A2 (en) 2008-03-27
CL2007002668A1 (es) 2008-05-09
AR062895A1 (es) 2008-12-10
KR20090059161A (ko) 2009-06-10
AU2007297652A1 (en) 2008-03-27
PE20080846A1 (es) 2008-08-23
CA2662613A1 (en) 2008-03-27
ES2444012T3 (es) 2014-02-21
US20110223160A1 (en) 2011-09-15
EA200970262A1 (ru) 2009-10-30
JP2010504331A (ja) 2010-02-12
MX353319B (es) 2018-01-05
CN101589062A (zh) 2009-11-25
EP2074149A2 (en) 2009-07-01
US7947809B2 (en) 2011-05-24
CN101589062B (zh) 2014-08-20
US20090041784A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
CR10736A (es) Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
CO7250445A2 (es) Proteínas de unión a antígeno st2
MX357193B (es) Moleculas de union anti-alfa sinucleina.
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
TN2015000247A1 (en) Bcma antigen binding proteins
AR083747A1 (es) Anticuerpos anti-il-23
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
NZ706377A (en) Il-6 antagonists and uses thereof
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
IN2014CN03936A (es)
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
NZ593964A (en) Human anti-alpha-synuclein autoantibodies
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
NZ602166A (en) Antibodies to il-6 and use thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
AR073140A1 (es) Anticuerpos anti-il-23r disenados
EA201000053A1 (ru) Новые антитела
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)